Chronic Kidney Disease - Pipeline Assessment and Market Forecasts to 2016

Chronic Kidney Disease - Pipeline Assessment and Market Forecasts to 2016

Summary

GlobalData, the industry analysis specialist’s new report, “Chronic Kidney Disease - Pipeline Assessment and Market Forecasts to 2016” is an essential source of information and analysis on the global chronic kidney disease market. The report identifies the key trends shaping and driving the global chronic kidney disease market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global chronic kidney disease sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key driver and challenges of the global CKD market. Its scope includes:

• Annualized global chronic kidney disease market revenues data from 2001 to 2009, forecast forward for 7 years to 2016.
• Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.
• Analysis of the current and future market competition in the global chronic kidney disease market.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the future market associated with chronic kidney disease.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global chronic kidney disease market.
• Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global chronic kidney disease market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global chronic kidney disease market landscape? – Identify, understand and capitalize.

Contents

1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 CHRONIC KIDNEY DISEASE MARKET: INTRODUCTION

2.1 GlobalData Pipeline Report Guidance

3 CHRONIC KIDNEY DISEASE MARKET: MARKET CHARACTERIZATION

3.1 Chronic Kidney Disease Market Size
3.2 Chronic Kidney Disease Market Forecast and CAGR
3.3 Drivers and Barriers for the Chronic Kidney Disease Market
  3.3.1 Drivers for the Chronic Kidney Disease Market
  3.3.2 Barriers for the Chronic Kidney Disease Market
3.4 Opportunity and Unmet Need
3.5 Key Takeaway

4 CHRONIC KIDNEY DISEASE MARKET: COMPETITIVE ASSESSMENT

4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles of the Major Marketed Products in the Chronic Kidney Disease Market
  4.3.1 Renagel (sevelamer hydrochloride)
  4.3.2 Renvela (sevelamer carbonate)
  4.3.3 Sensipar (cinacalcet hydrochloride)
  4.3.4 Feraheme (ferumoxytol)
  4.3.5 Fosrenol (lanthanum carbonate hydrate)
4.4 Key Takeaway

5 CHRONIC KIDNEY DISEASE MARKET: PIPELINE ASSESSMENT

5.1 Overview
5.2 Strategic Pipeline Assessment
  5.2.1 Technology Trends Analytic Framework
5.3 Chronic Kidney Disease Therapeutics – Promising Drugs under Clinical Development
5.4 Molecule Profile for Promising Drugs under Clinical Development
  5.4.1 Bardoxolone methyl
  5.4.2 MCI-196
  5.4.3 CTA018
  5.4.4 AST-120 (Kremezin)
5.5 Chronic Kidney Disease Therapeutics Market – Clinical Pipeline by Mechanism of Action
5.6 Chronic Kidney Disease Pipeline – Pipeline by Clinical Phases of Development
  5.6.1 Chronic Kidney Disease Therapeutics – Phase III Clinical Pipeline
  5.6.2 Chronic Kidney Disease Therapeutics – Phase II Clinical Pipeline
  5.6.3 Chronic Kidney Disease Therapeutics – Phase I Clinical Pipeline
  5.6.4 Chronic Kidney Disease Therapeutics – Preclinical Pipeline
  5.6.5 Discontinued / Suspended Drugs for Chronic Kidney Disease
5.7 Key Takeaway

6 CHRONIC KIDNEY DISEASE MARKET: IMPLICATIONS FOR FUTURE MARKET COMPETITION

Chronic Kidney Disease Market: Future Players in the Chronic Kidney Disease Market
6.1 Introduction
6.2 Novartis AG
  6.2.1 Company Overview
  6.2.2 Kidney Disease Portfolio
6.3 Reata Pharmaceuticals, Inc
  6.3.1 Company Overview
  6.3.2 Kidney Disease Portfolio
6.4 Mitsubishi Tanabe Pharma Corporation
  6.4.1 Company Overview
  6.4.2 Business Description
  6.4.3 Kidney Disease Portfolio
6.5 Cytochroma Inc
  6.5.1 Company Overview
  6.5.2 Kidney Disease Portfolio
6.6 Keryx Biopharmaceuticals
  6.6.1 Company Overview
  6.6.2 Business Description
  6.6.3 Kidney Disease Portfolio
6.7 Astellas Pharma Inc.
  6.7.1 Company Overview
  6.7.2 Business Description
  6.7.3 Kidney Disease Portfolio
6.8 FibroGen
  6.8.1 Company Overview
  6.8.2 Chronic Kidney Disease Portfolio

7 CHRONIC KIDNEY DISEASE MARKET: APPENDIX

7.1 Market Definition
7.2 Scope of Pipeline Research
7.3 Abbreviations
7.4 Research Methodology
  7.4.1 Coverage
  7.4.2 Secondary Research
  7.4.3 Forecasting
  7.4.4 Primary Research
  7.4.5 Expert Panels
7.5 Contact Us
7.6 Disclaimer
7.7 Sources

LIST OF TABLES

Table 1: Chronic Kidney Disease, Global, Revenue ($bn), 2001–2009
Table 2: Chronic Kidney Disease, Global, Market Forecast ($bn), 2009–2016
Table 3: Marketed Product Analysis for Chronic Kidney Disease, 2010
Table 4: Chronic Kidney Disease Therapeutics – Most Promising Drugs under Clinical Development, 2010
Table 5: Chronic Kidney Disease Pipeline, Phase III, 2010
Table 6: Chronic Kidney Disease Pipeline, Phase II, 2010
Table 7: Chronic Kidney Disease Pipeline, Phase I, 2010
Table 8: Chronic Kidney Disease Pipeline, Preclinical Phase, 2010
Table 9: Chronic Kidney Disease Pipeline, Discontinued / Suspended Drugs, 2010
Table 10: Novartis AG – Kidney Disease Portfolio, 2010
Table 11: Reata Pharmaceuticals – Kidney Disease Portfolio, 2010
Table 12: Mitsubishi Tanabe Pharma Corporation – Kidney Disease Portfolio, 2010
Table 13: Cytochroma – Kidney Disease Portfolio, 2010
Table 14: Keryx Biopharmaceuticals – Kidney Disease Portfolio, 2010
Table 15: Astellas – Kidney Disease Portfolio, 2010
Table 16: Fibrogen – Kidney Disease Portfolio, 2010

LIST OF FIGURES

Figure 1: Chronic Kidney Disease, Global, Revenue ($bn), 2001–2009
Figure 2: Chronic Kidney Disease, Global, Market Forecast ($bn), 2009–2016
Figure 3: Opportunity and Unmet Need in the Chronic Kidney Disease Market, 2010
Figure 4: Strategic Competitor Assessment of the Marketed Products for Chronic Kidney Disease, 2010
Figure 5: Technology Trends Analytic Framework of the Chronic Kidney Disease Pipeline, 2010
Figure 6: Technology Trends Analytic Framework of the Chronic Kidney Disease Pipeline – Description, 2010
Figure 7: Chronic Kidney Disease Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2010
Figure 8: Chronic Kidney Disease Pipeline by Phase of Clinical Development, 2010
Figure 9: Implications for Future Market Competition in the Chronic Kidney Disease Market, 2010
Figure 10: Chronic Kidney Disease Therapeutics Market – Clinical Pipeline by Company, 2010
Figure 11: GlobalData Methodology
Figure 12: GlobalData Market Forecasting Model

COMPANIES MENTIONED

Novartis AG
Reata Pharmaceuticals, Inc
Mitsubishi Tanabe Pharma Corporation
Cytochroma Inc
Keryx Biopharmaceuticals
Astellas Pharma Inc.
FibroGen Skip to top